Why the study?
Does digoxin prevent doxorubicin-induced cardiotoxicity in patients with gynaecological cancers receiving high doses of doxorubicin?
Population
n=29 patients with gynaecological cancers who received over 400 mg of doxorubicin
Comparison
Digoxin (n=17) or ouabain (n=6) vs No cardiac glycoside (n=6)
Design
Cohort
Authors
Loading...
May support digoxin to reduce doxorubicin ECG changes; leaves open need for randomized confirmation before practice change.
Does digoxin prevent doxorubicin-induced cardiotoxicity in patients with gynaecological cancers receiving high doses of doxorubicin?
Digoxin may prevent doxorubicin-induced electrocardiographical changes and cardiomyopathy in patients receiving high cumulative doses of doxorubicin.
Guthrie et al. (1977) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: